John A Bittl

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8738684/publications.pdf

Version: 2024-02-01

57758 17592 16,346 136 44 121 citations h-index g-index papers 141 141 141 11381 docs citations times ranked citing authors all docs

#	Article	lF	Citations
1	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2011, 58, e44-e122.	2.8	2,027
2	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. Circulation, 2011, 124, e574-651.	1.6	1,946
3	2016 ACC/AHA Guideline FocusedÂUpdate on Duration of DualÂAntiplatelet Therapy in Patients With Coronary Artery Disease. Journal of the American College of Cardiology, 2016, 68, 1082-1115.	2.8	1,232
4	Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared With Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2003, 289, 853.	7.4	1,074
5	2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Update of the Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease. Circulation, 2014, 130, 1749-1767.	1.6	685
6	2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2016, 67, 1235-1250.	2.8	684
7	2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. Journal of the American College of Cardiology, 2011, 58, e123-e210.	2.8	665
8	2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Update of the Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease. Journal of the American College of Cardiology, 2014, 64, 1929-1949.	2.8	656
9	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization. Journal of the American College of Cardiology, 2022, 79, e21-e129.	2.8	561
10	Treatment with Bivalirudin (Hirulog) as Compared with Heparin during Coronary Angioplasty for Unstable or Postinfarction Angina. New England Journal of Medicine, 1995, 333, 764-769.	27.0	497
11	Myonecrosis After Revascularization Procedures. Journal of the American College of Cardiology, 1998, 31, 241-251.	2.8	459
12	2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: Executive Summary. Circulation, 2011, 124, 2610-2642.	1.6	451
13	Long-term Efficacy of Bivalirudin and Provisional Clycoprotein IIb/IIIa Blockade vs Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Revascularization <subtitle>REPLACE-2 Randomized Trial</subtitle> . JAMA - Journal of the American Medical Association, 2004, 292, 696.	7.4	363
14	An Update on Radial Artery Access and Best Practices for Transradial Coronary Angiography and Intervention in Acute Coronary Syndrome: A Scientific Statement From the American Heart Association. Circulation: Cardiovascular Interventions, 2018, 11, e000035.	3.9	347
15	Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. American Heart Journal, 2001, 142, 952-959.	2.7	324
16	Predictors and Impact of Major Hemorrhage on Mortality Following Percutaneous Coronary Intervention from the REPLACE-2 Trial. American Journal of Cardiology, 2007, 100, 1364-1369.	1.6	315
17	Advances in Coronary Angioplasty. New England Journal of Medicine, 1996, 335, 1290-1302.	27.0	230
18	Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the) Tj ETQq0 0 0 rgBT /O	verlock 10 1.6	Tf 50 67 Td (F 215

Journal of Cardiology, 2004, 93, 1092-1096.

#	Article	IF	CITATIONS
19	Transcatheter umbrella closure of valvular and paravalvular leaks. Journal of the American College of Cardiology, 1992, 20, 1371-1377.	2.8	201
20	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2022, 145, CIR000000000001038.	1.6	177
21	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2022, 145, CIR000000000001039.	1.6	159
22	Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With CoronaryÂArtery Disease. Journal of the American College of Cardiology, 2016, 68, 1116-1139.	2.8	154
23	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary. Journal of the American College of Cardiology, 2022, 79, 197-215.	2.8	150
24	Coronary artery perforation during excimer laser coronary angioplasty. Journal of the American College of Cardiology, 1993, 21, 1158-1165.	2.8	139
25	Clinical success, complications and restenosis rates with excimer laser coronary angioplasty. American Journal of Cardiology, 1992, 70, 1533-1539.	1.6	137
26	Meta-Analysis of randomized trials of percutaneous transluminal coronary angioplasty versus atherectomy, cutting balloon atherotomy, or laser angioplasty. Journal of the American College of Cardiology, 2004, 43, 936-942.	2.8	109
27	Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2016. 134. e156-78.	1.6	105
28	Clinical Outcomes of Bivalirudin for Ischemic Heart Disease. Circulation, 1999, 100, 2049-2053.	1.6	101
29	Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention. Journal of the American College of Cardiology, 2003, 41, 386-393.	2.8	99
30	2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2013, 82, E266-355.	1.7	97
31	2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease. Journal of Thoracic and Cardiovascular Surgery, 2015, 149, e5-e23.	0.8	97
32	Bayesian Methods Affirm the Use of Percutaneous Coronary Intervention to Improve Survival in Patients With Unprotected Left Main Coronary Artery Disease. Circulation, 2013, 127, 2177-2185.	1.6	95
33	Catheter Interventions for Hemodialysis Fistulas and Grafts. JACC: Cardiovascular Interventions, 2010, 3, 1-11.	2.9	94
34	Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. American Journal of Cardiology, 2003, 92, 919-923.	1.6	92
35	Effect of intracoronary saline infusion on dissection during excimer laser coronary angioplasty: A randomized trial. Journal of the American College of Cardiology, 1995, 26, 1264-1269.	2.8	89
36	Acute complications of excimer laser coronary angioplasty: A detailed analysis of multicenter results. Journal of the American College of Cardiology, 1994, 23, 1305-1313.	2.8	85

#	Article	IF	CITATIONS
37	No-touch technique for reducing aortic wall trauma during renal artery stenting. Catheterization and Cardiovascular Interventions, 1999, 46, 245-248.	1.7	76
38	Analysis and Comparison of Operator-Specific Outcomes in Interventional Cardiology. Circulation, 1996, 93, 431-439.	1.6	66
39	Orthodeoxia-platypnea due to intracardiac shunting relief with transcatheter double umbrella closure. Catheterization and Cardiovascular Diagnosis, 1995, 36, 247-250.	0.3	64
40	Bayesian Analysis: A Practical Approach to Interpret Clinical Trials and Create Clinical Practice Guidelines. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	64
41	Relation between clinical presentation and angiographic findings in unstable angina pectoris, and comparison with that in stable angina. American Journal of Cardiology, 1993, 72, 544-550.	1.6	62
42	PCI Strategies in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel CoronaryÂArteryÂDisease. Journal of the American College of Cardiology, 2016, 68, 1066-1081.	2.8	60
43	Antithrombotic Therapy in Patients Undergoing Coronary Angioplasty. Chest, 1995, 108, 486S-501S.	0.8	56
44	Length of Hospital Stay and Complications After Percutaneous Transluminal Coronary Angioplasty. Circulation, 1995, 92, 311-319.	1.6	46
45	Excimer laser-facilitated angioplasty for undilatable coronary narrowings. American Journal of Cardiology, 1996, 78, 1045-1047.	1.6	45
46	Antithrombotic Therapy in Patients Undergoing Coronary Angioplasty. Chest, 1998, 114, 728S-741S.	0.8	44
47	Cutting balloon angioplasty for undilatable venous stenoses causing dialysis graft failure. Catheterization and Cardiovascular Interventions, 2003, 58, 524-526.	1.7	42
48	A randomized comparison of bivalirudin and heparin in patients undergoing coronary angioplasty for postinfarction angina. American Journal of Cardiology, 1998, 82, 43P-49P.	1.6	41
49	Relation between abrupt vessel closure and the anticoagulant response to heparin or bivalirudin during coronary angioplasty. American Journal of Cardiology, 1998, 82, 50P-56P.	1.6	34
50	Venous rupture during percutaneous treatment of hemodialysis fistulas and grafts. Catheterization and Cardiovascular Interventions, 2009, 74, 1097-1101.	1.7	34
51	Biochemical responses of myocardial cells in culture to oxygen and glucose deprivation. Biochemical and Biophysical Research Communications, 1974, 59, 749-756.	2.1	31
52	Analysis of late lumen narrowing after excimer laser-facilitated coronary angioplasty. Journal of the American College of Cardiology, 1994, 23, 1314-1320.	2.8	31
53	Effect of direct thrombin inhibition with Bivalirudin (Hirulog) on restenosis after coronary angioplasty. American Journal of Cardiology, 1998, 82, 511-515.	1.6	30
54	Concomitant Peripheral Arterial Disease and Coronary Artery Disease. Circulation, 2004, 109, 3136-3144.	1.6	30

#	Article	IF	CITATIONS
55	Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: An analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial. American Heart Journal, 2006, 152, 149-154.	2.7	28
56	Early and Late Quantitative Angiographic Results of Vein Graft Lesions Treated by Excimer Laser With Adjunctive Balloon Angioplasty. Circulation, 1995, 92, 348-356.	1.6	28
57	Excimer Laser Coronary Angioplasty: The New Approaches to Coronary Intervention (NACI) Experience. American Journal of Cardiology, 1997, 80, 99K-105K.	1.6	27
58	Percutaneous Coronary Interventions in the Diabetic Patient. Circulation: Cardiovascular Interventions, 2015, 8, e001944.	3.9	27
59	Directional Coronary Atherectomy versus Balloon Angioplasty. New England Journal of Medicine, 1993, 329, 273-274.	27.0	26
60	Coronary stent occlusion: Thrombus horribilis. Journal of the American College of Cardiology, 1996, 28, 368-370.	2.8	26
61	Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention. European Heart Journal, 2005, 26, 2396-2403.	2.2	24
62	Successful treatment of an excimer laser-associated coronary artery perforation with the stack perfusion catheter. Catheterization and Cardiovascular Diagnosis, 1991, 22, 118-123.	0.3	22
63	Economic analysis of angiography and preemptive angioplasty to prevent hemodialysisâ€access thrombosis. Catheterization and Cardiovascular Interventions, 2010, 75, 14-21.	1.7	21
64	Bivalirudin Compared With Heparin During Coronary Angioplasty for Thrombus-Containing Lesions. Journal of the American College of Cardiology, 1997, 30, 1264-1269.	2.8	19
65	Effect of transient abrupt vessel closure during otherwise successful angioplasty for unstable angina on clinical outcome at six months. Journal of the American College of Cardiology, 1999, 33, 73-78.	2.8	19
66	Coronary Flow Velocity and Disturbed Flow Predict Adverse Clinical Outcome After Coronary Angioplasty. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1334-1340.	2.4	16
67	Prospective assessment of hemodialysis access patency after percutaneous intervention: Cox proportional hazards analysis. Catheterization and Cardiovascular Interventions, 2005, 66, 309-315.	1.7	16
68	Laser wire for crossing chronic total occlusions: "Learning phase―results from the U.S. TOTAL trial. , 1998, 44, 235-243.		13
69	Provisional glycoprotein Ilb/Illa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein Ilb/Illa inhibition during percutaneous coronary intervention: Predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)–2 trial. American Heart Journal. 2006. 152. 157-163.	2.7	13
70	Physical aspects of excimer laser angioplasty for undilatable lesions. Catheterization and Cardiovascular Interventions, 2008, 71, 808-809.	1.7	13
71	Outcomes after multivessel or culpritâ€Vessel intervention for <scp>ST</scp> â€elevation myocardial infarction in patients with multivessel coronary disease: A <scp>B</scp> ayesian crossâ€design metaâ€analysis. Catheterization and Cardiovascular Interventions, 2015, 86, S15-22.	1.7	13
72	Factors Affecting Bleeding and Stent Thrombosis in Clinical Trials Comparing Bivalirudin With Heparin During Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2015, 8, e002789.	3.9	13

#	Article	IF	Citations
73	The Changing Profile of Patient Selection, Procedural Techniques, and Outcomes in Excimer Laser Coronary Angioplasty. Journal of Interventional Cardiology, 1995, 8, 653-660.	1.2	10
74	Cholesterol embolization syndrome: Unifying principles. Catheterization and Cardiovascular Interventions, 2000, 51, 326-327.	1.7	9
75	Treatment of Atherosclerotic Renovascular Disease. New England Journal of Medicine, 2014, 370, 78-79.	27.0	9
76	Metaâ€analysis of randomized controlled trials comparing percutaneous coronary intervention with aspiration thrombectomy Vs. Conventional percutaneous coronary intervention during STâ€segment elevation myocardial infarction. Catheterization and Cardiovascular Interventions, 2016, 87, 1203-1210.	1.7	9
77	Much Ado About Nothing?. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	9
78	Percutaneous therapy of dialysis access failure. Catheterization and Cardiovascular Interventions, 2002, 56, 157-161.	1.7	8
79	Adaptive remodeling of hypoplastic hemodialysis fistulas salvaged with angioplasty. Catheterization and Cardiovascular Interventions, 2009, 73, 974-978.	1.7	8
80	Bioresorbable Stents. Circulation, 2010, 122, 2236-2238.	1.6	8
81	Excimer laser angioplasty: Focus on total occlusions. American Journal of Cardiology, 1996, 78, 823-824.	1.6	6
82	Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction. JAMA Cardiology, 2016, 1, 226.	6.1	6
83	Peak left ventricular pressure during percutaneous aortic balloon valvuloplasty: Clinical and echocardiographic correlations. Journal of the American College of Cardiology, 1989, 14, 135-142.	2.8	5
84	Using Absolute Event Rates to See What Works in Cardiovascular Medicine. Journal of the American College of Cardiology, 2017, 70, 1376-1378.	2.8	5
85	Bayes Factor Meta-Analysis of the Mortality Claim for Peripheral Paclitaxel-Eluting Devices. JACC: Cardiovascular Interventions, 2019, 12, 2528-2537.	2.9	5
86	Damage Control for Renal Artery Stenting. Circulation, 2008, 117, 2724-2726.	1.6	4
87	Abciximab During Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2013, 61, 1455-1457.	2.8	4
88	A proposal to reduce contrast nephropathy: Eliminate the NPO order. Catheterization and Cardiovascular Interventions, 2014, 83, 913-914.	1.7	4
89	Deconstructing Stent Polymers. Journal of the American College of Cardiology, 2014, 63, 308-309.	2.8	4
90	Dual-Antiplatelet Therapy for DiabeticÂPatients After Stent Implantation. Journal of the American College of Cardiology, 2015, 66, 1102-1104.	2.8	4

#	Article	IF	CITATIONS
91	The Tradeoff Between Shorter and Longer Courses of Dual Antiplatelet Therapy After Implantation of Newer Generation Drug-Eluting Stents. Current Cardiology Reports, 2016, 18, 8.	2.9	4
92	The ABCD-GENE Score for ClopidogrelÂResponse. JACC: Cardiovascular Interventions, 2020, 13, 618-620.	2.9	4
93	The truth about activated clotting time measurements. Catheterization and Cardiovascular Interventions, 2005, 65, 338-339.	1.7	3
94	The Future of an IllusionâŽâŽEditorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology Journal of the American College of Cardiology, 2006, 47, 2380-2383.	2.8	3
95	Chelation Therapy and Cardiovascular Outcomes. JAMA - Journal of the American Medical Association, 2013, 310, 430.	7.4	3
96	Family presence during catheterization procedures. Catheterization and Cardiovascular Interventions, 2014, 83, 341-341.	1.7	3
97	Treatment of Bifurcation Lesions. Journal of the American College of Cardiology, 2015, 65, 544-545.	2.8	3
98	How long should dual antiplatelet therapy be used in diabetic patients after implantation of drug-eluting stents?. Current Opinion in Cardiology, 2016, 31, 677-682.	1.8	3
99	The Prematurely Stopped Clinical Trial. JACC: Cardiovascular Interventions, 2017, 10, 1199-1201.	2.9	3
100	When to Believe Unexpected Results for Ticagrelor or Prasugrel. JACC: Cardiovascular Interventions, 2020, 13, 2248-2250.	2.9	3
101	Bayesian Inference Supports the Use of Bypass Surgery Over Percutaneous Coronary Intervention To Reduce Mortality in Diabetic Patients with Multivessel Coronary Disease. International Journal of Statistics in Medical Research, 2015, 4, 26-34.	1.0	3
102	Gastrointestinal Injury Caused by Aspirin or Clopidogrel Monotherapy Versus Dual Antiplatelet Therapy. Journal of the American College of Cardiology, 2021, 79, 129-129.	2.8	3
103	Wire-Guided Excimer Laser Coronary Angioplasty: Instrument Selection, Lesion Characterization, and Operator Technique. Journal of Interventional Cardiology, 1992, 5, 275-291.	1.2	2
104	From confusion to clarity: Direct thrombin inhibitors for patients with heparin-induced thrombocytopenia. Catheterization and Cardiovascular Interventions, 2001, 52, 473-475.	1.7	2
105	Extended Dual Antiplatelet Therapy in Patients With Prior Myocardial Infarction. JAMA Cardiology, 2016, 1, 629.	6.1	2
106	A Swing and a Miss for the DAPT Score. Journal of the American College of Cardiology, 2018, 72, 1079-1080.	2.8	2
107	Laser wire for crossing chronic total occlusions: "Learning phase―results from the U.S. TOTAL trial. Catheterization and Cardiovascular Diagnosis, 1998, 44, 235-243.	0.3	2
108	Putting the 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization Into Practice. JACC: Case Reports, 2022, 4, 31-35.	0.6	2

#	Article	IF	CITATIONS
109	Mitral Valve Balloon Dilatation: Long-Term Results. Journal of Cardiac Surgery, 1994, 9, 213-217.	0.7	1
110	Creatine kinase leaks, myocardial necrosis, and prognosis after percutaneous coronary interventions. Catheterization and Cardiovascular Interventions, 1999, 46, 303-304.	1.7	1
111	Optimizing the benefits of renal artery stenting. Catheterization and Cardiovascular Interventions, 1999, 47, 173-174.	1.7	1
112	Why Radial Access Is Better. JACC: Cardiovascular Interventions, 2016, 9, 1435-1437.	2.9	1
113	Bleeding Versus Ischemic Events. JACC: Cardiovascular Interventions, 2016, 9, 2387-2389.	2.9	1
114	Invasive Cardiac Procedures Increase Bleeding in Frail Patients With AcuteÂMyocardial Infarction. JACC: Cardiovascular Interventions, 2018, 11, 2297-2299.	2.9	1
115	Using Ticagrelor to Prevent Recurrent Type 1 and Type 2 Myocardial Infarctions: Boon or Bane?. Journal of the American Heart Association, 2018, 7, e010996.	3.7	1
116	Integrating the ABC-Bleeding Risk Score Into Practice. JAMA Network Open, 2020, 3, e2016126.	5.9	1
117	Dialysis access intervention: Techniques for the interventional cardiologist. Progress in Cardiovascular Diseases, 2021, 65, 84-88.	3.1	1
118	Does Platelet Reactivity Testing Predict Post-Operative Bleeding Risk?. Journal of the American College of Cardiology, 2021, 77, 1287-1289.	2.8	1
119	Antithrombotic Therapy after Acute Coronary Syndromes. New England Journal of Medicine, 2021, 384, 1872-1874.	27.0	1
120	Does Bypass Surgery or Percutaneous Coronary Intervention Improve Survival in Stable Ischemic Heart Disease?. JACC: Cardiovascular Interventions, 2022, , .	2.9	1
121	Excimer Laser Coronary Angioplasty. Cardiology Clinics, 1994, 12, 585-593.	2.2	0
122	A safety net for saphenous vein graft perforations. Catheterization and Cardiovascular Interventions, 1999, 48, 387-387.	1.7	0
123	Cardiovascular disease in dialysis patients: Double trouble. Catheterization and Cardiovascular Interventions, 2001, 54, 464-465.	1.7	0
124	Argatroban for percutaneous coronary interventions: Hit or miss?. Catheterization and Cardiovascular Interventions, 2002, 57, 185-186.	1.7	0
125	Beware of large treatment effects in small clinical trials: Lessons from trials of coronary atheroablative devices. Catheterization and Cardiovascular Interventions, 2013, 81, 292-293.	1.7	0
126	Response to Letters Regarding Article, "Bayesian Methods Affirm the Use of Percutaneous Coronary Intervention to Improve Survival in Patients With Unprotected Left Main Coronary Artery Disease― Circulation, 2014, 129, e309.	1.6	0

#	Article	IF	Citations
127	Go Set a Watchman?. JACC: Cardiovascular Interventions, 2015, 8, 1933-1934.	2.9	O
128	Percutaneous Coronary Intervention for Chronic Total Occlusions. JACC: Cardiovascular Interventions, 2015, 8, 254-256.	2.9	0
129	Everolimus-Eluting Coronary Stents for Patients With Chronic Kidney Disease. Journal of the American College of Cardiology, 2015, 66, 1221-1223.	2.8	O
130	What Do Noninferiority Trials Say AboutÂCoronary Stents?. JACC: Cardiovascular Interventions, 2017, 10, 265-267.	2.9	0
131	Treatment Strategies for Patients With ST-Segment Elevation Myocardial Infarction and MultivesselÂDisease. JACC: Cardiovascular Interventions, 2017, 10, 206-207.	2.9	O
132	Bivalirudin or heparin for radial access?. Catheterization and Cardiovascular Interventions, 2017, 89, 1166-1167.	1.7	0
133	Percutaneous Coronary Intervention for Chronic Total Occlusions. Circulation: Cardiovascular Interventions, 2020, 13, e008920.	3.9	O
134	Multivessel Percutaneous Coronary Intervention During ST-Elevation Myocardial Infarctionâ€"A Dickensian Debate That Never Ends. JAMA Cardiology, 2021, 6, 580.	6.1	0
135	Interventions for Failing Hemodialysis Access. , 2013, , 421-429.		O
136	DAPT rules. EuroIntervention, 2018, 13, 1864-1868.	3.2	0